Replies to post #147078 on Biotech Values

[mcbio]

ARRY - I gather that one reason for the positive reaction could be that the PR states that there could be a P3 for selumetinib completed by 2013. That's intriguing if I understood it correctly. Sounds like a small trial powered for PFS if true. Do you recall this being addressed during the CC?

No, not completed I don't believe. The reference to five potential Phase 3 decisions by end of 2013 in the PR was to having pivotal trials started by that timeframe.